Search

Your search keyword '"Vitello, P."' showing total 467 results
Start Over Author "Vitello, P."
467 results on '"Vitello, P."'

451. Treating sludge VOCs, odors

Author

Vitello, William F.

Subjects
ODOR control, ORGANIC compounds, EMISSIONS (Air pollution), SLUDGE management, REACTIVITY (Chemistry)
Published
1992

458. Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania ‘Luigi Vanvitelli’

Author

Stefania Napolitano, Davide Ciardiello, L. Poliero, Ferdinando De Vita, M. Terminiello, Morena Fasano, Emilio Francesco Giunta, Vincenzo De Falco, P. Vitale, Teresa Troiani, Francesca Carlino, Renato Franco, Raimondo Di Liello, Vincenzo Famiglietti, N. Zanaletti, V. Caputo, Carminia Maria Della Corte, Anna Ventriglia, Michele Orditura, Lucia Altucci, Giulia Martini, Floriana Morgillo, Fortunato Ciardiello, Erika Martinelli, Pietro Paolo Vitiello, De Falco, V., Poliero, L., Vitello, P. P., Ciardiello, D., Vitale, P., Zanaletti, N., Giunta, E. F., Terminiello, M., Caputo, V., Carlino, F., Di Liello, R., Ventriglia, A., Famiglietti, V., Martinelli, E., Morgillo, F., Orditura, M., De Vita, F., Fasano, M., Napolitano, S., Martini, G., Della Corte, C. M., Franco, R., Altucci, L., Ciardiello, F., and Troiani, T.

Subjects
Oncology, Cancer Research, medicine.medical_specialty, foundationone, Colorectal cancer, Population, medicine.disease_cause, Breast cancer, Internal medicine, medicine, Lung cancer, education, Original Research, education.field_of_study, Performance status, business.industry, comprehensive genomic profiling, CGP, Cancer, medicine.disease, NGS, next-generation sequencing, KRAS, Ovarian cancer, business
Abstract

Background The emerging role of next-generation sequencing (NGS) targeted panels is revolutionising our approach to cancer patients, providing information on gene alterations helpful for diagnosis and clinical decision, in a short time and with acceptable costs. Materials and methods In this work, we evaluated the clinical application of FoundationOne CDx test, a hybrid capture-based NGS. This test identifies alterations in 324 genes, tumour mutational burden and genomic signatures as microsatellite instability. The decision to obtain the NGS assay for a particular patient was done according to investigator's choice. Results Overall, 122 tumour specimens were analysed, of which 84 (68.85%) succeeded. The success rate was influenced by type of specimen formalin-fixed paraffin embedded (FFPE block vs FFPE slides), by origin of the sample (surgery vs biopsy) and by time of fixation (

Published
2020

467. Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature.

Author

Croce F, Vitello P, Dalla Pria A, Riva A, Galli M, and Antinori S

Subjects
Alanine Transaminase blood, Aspartate Aminotransferases blood, Creatine Kinase blood, Female, HIV Infections blood, HIV Infections drug therapy, HIV Integrase Inhibitors therapeutic use, Humans, L-Lactate Dehydrogenase blood, Middle Aged, Pyrrolidinones therapeutic use, Raltegravir Potassium, Rhabdomyolysis blood, Rhabdomyolysis diagnosis, HIV Integrase Inhibitors adverse effects, Pyrrolidinones adverse effects, Rhabdomyolysis chemically induced
Abstract

Raltegravir (RAL), an HIV integrase inhibitor, may uncommonly induce an increase of serum creatine kinase (CK) both in naïve and antiretroviral (ARV)-experienced HIV-positive patients. We report the case of severe rhabdomyolysis requiring hospitalization in an ARV-experienced HIV/hepatitis C co-infected patient treated with a RAL-containing drug regimen. Factors favouring a severe clinical occurrence of RAL-induced rhabdomyolysis from cases reported in literature are described.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results